Hisamitsu Agrees On Joint Sales With Asahi Kasei For Overactive Bladder Drug
This article was originally published in PharmAsia News
Executive Summary
Hisamitsu Pharmaceuticals signed a joint sales agreement with Asahi Kasei Pharmaceuticals for HOB-294 (oxybutynin) for overactive bladder treatment, the company announced Dec. 10.